BRIAIN生物技术公司和Akribion公司为G-dase E CRISPR-Cas技术公司签发的G-daseé E CRISPR-Cas治疗标志许可证协议。 BRAIN Biotech and Akribion Therapeutics sign licensing deal for G-dase® E CRISPR-Cas tech.

BRIAIN生物技术集团和Akribion治疗公司已就G-dase E CRISPR-Cas技术签订了一项独家许可证协议,目的是加强肿瘤学和其他领域的治疗。 BRAIN Biotech AG and Akribion Therapeutics GmbH have entered into an exclusive licensing agreement for the G-dase® E CRISPR-Cas technology, aiming to enhance treatments in oncology and other areas. 根据Akribion的临床发展和市场业绩,这项交易包括向BRAIN提供最高达9,230万欧元的潜在里程碑费,以及净销售费。 The deal includes potential milestone fees up to EUR 92.3 million for BRAIN, based on Akribion's clinical development and market performance, alongside royalties on net sales. 协议须遵守标准的关闭条件。 The agreement is subject to standard closing conditions.